Efficacy of lamivudine on hepatitis B viral status and liver function in patients with hepatitis B virus-related hepatocellular carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Ji Hoon | - |
dc.contributor.author | Park, Joong-Won | - |
dc.contributor.author | Koh, Dong Wook | - |
dc.contributor.author | Lee, Woo Jin | - |
dc.contributor.author | Kim, Chang-Min | - |
dc.date.available | 2020-11-03T08:47:52Z | - |
dc.date.issued | 2009-02 | - |
dc.identifier.issn | 1478-3223 | - |
dc.identifier.issn | 1478-3231 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/16246 | - |
dc.description.abstract | Treatment of patients with hepatocellular carcinoma (HCC) depends on the tumour extent and underlying liver function. Antiviral therapy with nucleoside/nucleotide analogues has been shown to be effective in improving the liver function of chronic hepatitis B (CHB) patients. We assessed whether lamivudine could induce biochemical and virological improvements in patients with hepatitis B virus-related HCC. Of 148 CHB patients treated with 100 mg/day lamivudine for at least 6 months, 80 had HCC (CHB/HCC group) and 68 did not (CHB group). Biochemical and virological parameters were serially monitored. Compared with the CHB group, the CHB/HCC group was older, had higher male predominance, bilirubin levels and liver cirrhosis rate, and lower albumin and hepatitis B virus (HBV) DNA levels and hepatitis B e antigen (HBeAg) positivity (P < 0.05 each). The two groups showed similar cumulative rates of alanine aminotransferase normalization, HBV DNA seroconversion, HBeAg loss and viral breakthrough during 12 months of lamivudine treatment. After 12 months, the CHB/HCC group showed, relative to baseline, increased albumin levels (3.51 +/- 0.5 vs. 3.72 +/- 0.5 mg/ml) and decreased ascites scores (1.63 +/- 0.7 vs. 1.45 +/- 0.6) and Child-Pugh scores (6.92 +/- 1.9 vs. 6.02 +/- 1.38) (P < 0.05 each). Lamivudine had comparable antiviral effects both in patients with CHB and CHB/HCC, and improved underlying liver function in the latter group. Treatment of HBV may increase the chance of curative treatments in patients with HBV-related HCC. | - |
dc.format.extent | 5 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | WILEY | - |
dc.title | Efficacy of lamivudine on hepatitis B viral status and liver function in patients with hepatitis B virus-related hepatocellular carcinoma | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1111/j.1478-3231.2008.01828.x | - |
dc.identifier.scopusid | 2-s2.0-58149510581 | - |
dc.identifier.wosid | 000262284100012 | - |
dc.identifier.bibliographicCitation | LIVER INTERNATIONAL, v.29, no.2, pp 203 - 207 | - |
dc.citation.title | LIVER INTERNATIONAL | - |
dc.citation.volume | 29 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 203 | - |
dc.citation.endPage | 207 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | NATURAL-HISTORY | - |
dc.subject.keywordPlus | DECOMPENSATED CIRRHOSIS | - |
dc.subject.keywordPlus | REACTIVATION | - |
dc.subject.keywordPlus | INFECTION | - |
dc.subject.keywordPlus | RESECTION | - |
dc.subject.keywordPlus | PREVENTION | - |
dc.subject.keywordAuthor | chronic hepatitis B | - |
dc.subject.keywordAuthor | efficacy | - |
dc.subject.keywordAuthor | hepatocellular carcinoma | - |
dc.subject.keywordAuthor | lamivudine | - |
dc.subject.keywordAuthor | liver function | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.